Abiraterone Acetate

證據等級: L5

預測適應症: 0 個

Abiraterone Acetate: Evaluation Pending — No Predicted Indication Available

One-Sentence Summary

Abiraterone acetate is a CYP17A1 inhibitor originally developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The TxGNN model has not yet generated a predicted new indication for this drug. The current evidence pack contains significant data gaps that must be resolved before evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Metastatic castration-resistant prostate cancer (mCRPC)¹
Predicted New Indication	— (No prediction available)
TxGNN Prediction Score	—
Evidence Level	L5 (No prediction or supporting studies)
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

¹ Based on globally established use; no TFDA licence data available in this evidence pack.

Why is This Prediction Reasonable?

Currently, no new indication has been predicted by TxGNN for abiraterone acetate, so mechanistic plausibility cannot be assessed at this time.

For context, abiraterone acetate is a prodrug of abiraterone, which irreversibly inhibits CYP17A1 (17α-hydroxylase/C17,20-lyase), a key enzyme in androgen biosynthesis. By blocking androgen production in the testes, adrenal glands, and prostate tumour tissue, it suppresses tumour growth driven by androgen receptor signalling. It is globally approved (FDA, EMA) for use in combination with prednisone for mCRPC and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Detailed mechanism of action data was not included in the evidence pack (identified as Data Gap DG002). Once TxGNN generates a predicted indication, the MOA data should be retrieved from DrugBank to assess whether the CYP17A1 inhibition pathway — or secondary pharmacological effects — could be relevant to the new target disease.

Clinical Trial Evidence

Currently no predicted indication has been generated; therefore, no indication-specific clinical trial search was performed.

Literature Evidence

Currently no predicted indication has been generated; therefore, no indication-specific literature search was performed.

Taiwan Market Information

Abiraterone acetate has no TFDA-approved licences recorded in this evidence pack. The drug is listed as "Not marketed" in Taiwan.

Cytotoxicity

Abiraterone acetate is an antineoplastic agent (androgen biosynthesis inhibitor) and therefore requires cytotoxicity consideration.

Item	Content
Cytotoxicity Classification	Targeted therapy (Hormonal / Androgen biosynthesis inhibitor)
Myelosuppression Risk	Low (not a conventional cytotoxic; anaemia is a known adverse effect)
Emetogenicity Classification	Low
Monitoring Items	Liver function (ALT/AST — hepatotoxicity risk), blood pressure, serum potassium, serum cortisol, CBC, cardiac function
Handling Protection	Standard precautions; not classified as conventional cytotoxic — no special closed-system handling required, but pregnant women should avoid handling crushed/broken tablets

Safety Considerations

No TFDA package insert data, warnings, contraindications, or drug–drug interaction data were available in this evidence pack.

Please refer to the package insert for safety information. Key safety concerns known globally include:

Hepatotoxicity — ALT/AST elevations requiring monitoring

Mineralocorticoid excess — Hypertension, hypokalaemia, fluid retention (due to CYP17A1 blockade upstream of mineralocorticoid synthesis)

Adrenocortical insufficiency — Requires concomitant corticosteroid administration

Cardiac disorders — Cardiac failure, atrial fibrillation reported

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model has not yet produced a predicted new indication for abiraterone acetate, and there are multiple blocking data gaps (TFDA labelling, MOA data). Without a target indication, no evidence-level assessment or go/no-go recommendation can be made.

To proceed, the following is needed:

Run TxGNN prediction pipeline for abiraterone acetate to generate candidate indications
Resolve DG001 (Blocking): Retrieve TFDA package insert warnings and contraindications, or note that the drug is not marketed in Taiwan and source safety data from FDA/EMA labels instead
Resolve DG002 (High): Query DrugBank for MOA and pharmacological classification (DrugBank ID: DB05812)
Clarify Taiwan regulatory pathway — if the drug is not marketed in Taiwan, determine whether a TFDA import pathway or special access scheme applies
Re-generate the evidence pack once the above gaps are filled and TxGNN predictions are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.